CLINUVEL progresses vitiligo treatment program
Novel approach to addressing pigment loss disorder affecting an estimated 45 million individuals worldwide...
Positive final results in stroke
World-first stroke study CUV801 evaluating afamelanotide...
Letter to shareholders from CLINUVEL’s CEO
LONDON, April 29, 2022 (GLOBE NEWSWIRE) -- Â Â Â Dear shareholders, friends, Both from a professional viewpoint and as largest private holder, I have...